Project Grant R35GM166109
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $616,000 on March 12, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop next-generation proximity labeling enzymes for mapping spatial proteomes in living cells. The research aims to engineer and optimize FLEXID and LACCID, two proximity labeling enzymes designed to overcome limitations of existing methods like APEX and TURBOID in specificity, sensitivity, and...
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $125,000 under the Biomedical Research and Research Training program (CFDA 93.859) on May 1, 2026, to develop membrane-centric proximity labeling approaches for mapping lipid-protein and protein-protein networks in live cells. The work targets transient and context-dependent membrane interactions that remain difficult to study with conventional tools. The recipient will engineer conditionally...
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $1.924 million on August 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate how nuclear mechanical properties regulate cell functions independently of gene expression. The research examines whether and how mechanical properties of the nucleus—including size, stiffness, and integrity—control essential cellular processes such as migration, proliferation,...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $421,456 on July 1, 2026, to discover and engineer biosynthetic pathways from plant natural products for therapeutic development under the Biomedical Research and Research Training program (CFDA 93.859). The award funds research to characterize complete biosynthetic pathways of clinically approved plant-derived...
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $304,000 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and apply adaptive optical tweezers for probing live cell membrane tension dynamics in health and disease states. The funded research focuses on quantifying physical forces and mechanical properties governing cellular processes, particularly cell membrane tension during mitosis. The...
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $236,736 on August 9, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop chemically induced proximity methodology for rewiring nucleosome engagement patterns. The project runs through April 30, 2028, with work performed in Palo Alto, California. The funded research applies bivalent molecules that bind and bring together two biomolecules to promote the...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $1,733,072 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a multi-resolution open-top light-sheet expansion microscopy system. The project will advance 3D microscopy for high-throughput imaging of expanded tissues with ultra-high resolution—sub-150 nanometer...
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $423,500 on March 6, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to dissect the molecular mechanisms of membrane protein complex assembly at the human endoplasmic reticulum. The project investigates how thousands of membrane proteins find correct binding partners to assemble into functional complexes of defined stoichiometry, using voltage-gated ion channels...
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $431,563 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop chemical tools for studies of ion channel function and physiology. The work focuses on creation of small-molecule chemical agents—including modified natural toxins, fluorescence imaging probes, photochemical cross-linking agents, and subtype-specific inhibitors—to enable investigation...
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $2.117 million on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The award funds development of artificial intelligence and machine learning methods to integrate electronic health record data with high-dimensional omics data modalities—specifically proteomics and...
The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $364,910 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to engineer enzyme-responsive elastin-like polypeptides that direct biomolecular phase behavior for applications in regenerative tissue engineering, controlled drug delivery, and scalable therapeutic biomolecule production. The recipient will develop stimuli-responsive biopolymers triggered by proteolytic enzymes rather than heat, light, or pH changes, enabling phase transformations compatible with biological systems where organisms and cells require tightly regulated conditions. The work will investigate logic-gated control of phase behavior, enzyme-activated assembly of extended-release therapeutic biomaterials, and intracellular regulation of biomolecular condensation processes. The research builds on the investigator's prior design of protease-responsive elastin-like polypeptides that form coacervate phases upon isothermal cleavage, creating a modular, tunable platform responsive to different proteases for general medicine and disease treatment applications. Performance runs from September 1, 2026 through April 30, 2031, with work performed in Palo Alto, California.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $364.9k | 8/17/26 |